Serum Fstl1, a novel biomarker screened based on protein array technology, predict acute kidney injury and major renal adverse events after cardiac surgery: A prospective cohort study

Hong Lang,Hang Zhang,Mengqing Ma,Xin Wan,Yuyang Chen,Qing Sun,Changchun Cao

Clinica Chimica Acta（2023）

Cited 1|Views14

No score

Abstract

•Serum follistatin-like 1(Fstl1) can be used for early identification of cardiac surgery–associated AKI (CSA-AKI) and major renal adverse events.•Serum Fstl1 can be used as an important indicator for CSA-AKI model optimization.•Protein microarray technology can be used as a reliable method to detect CSA-AKI.

Translated text

Key words

Acute kidney injury,Cardiac surgery,Protein array technology,Follistatin-like 1,Prediction

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined